Module
Update on Adjuvant Hormonal Therapy for Breast Cancer
Source: Breast Cancer Annual Update 2005
Update on Adjuvant Hormonal Therapy for Breast Cancer
Program Director: Clifford A. Hudis, MD
|
Learning ObjectivesUpon completion of this activity, participants should be able to:
Review the most recent data from pivotal hormonal therapy trials in women with breast cancer. Describe the role of adjuvant hormonal therapy in breast cancer, with particular regard for differing patient characteristics. Evaluate the relative efficacy and safety of tamoxifen, anastrozole, letrozole, and exemestane.
Content includes:
-
Tamoxifen
-
Aromatase Inhibitors: Options for Postmenopausal Women
-
Aromatase Inhibitors as Initial Adjuvant Therapy
-
Sequential Therapy with Tamoxifen and an Aromatase Inhibitor
-
Extended Adjuvant Hormonal Therapy: Aromatase Inhibitors After Tamoxifen
-
Options for Premenopausal Women: Ovarian Ablation
-
Biomarkers
|
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
|
|